TY - JOUR
T1 - Cannabis use as a potential mediator between childhood adversity and first-episode psychosis: results from the EU-GEI case–control study
AU - Trotta, Giulia
AU - Rodriguez, Victoria
AU - Quattrone, Diego
AU - Spinazzola, Edoardo
AU - Tripoli, Giada
AU - Gayer-Anderson, Charlotte
AU - Freeman, Tom p
AU - Jongsma, Hannah e
AU - Sideli, Lucia
AU - Aas, Monica
AU - Stilo, Simona a
AU - La cascia, Caterina
AU - Ferraro, Laura
AU - La barbera, Daniele
AU - Lasalvia, Antonio
AU - Tosato, Sarah
AU - Tarricone, Ilaria
AU - D'andrea, Giuseppe
AU - Tortelli, Andrea
AU - Schürhoff, Franck
AU - Szöke, Andrei
AU - Pignon, Baptiste
AU - Selten, Jean-Paul
AU - Velthorst, Eva
AU - De haan, Lieuwe
AU - Llorca, Pierre-Michel
AU - Rossi menezes, Paulo
AU - Del ben, Cristina m
AU - Santos, Jose luis
AU - Arrojo, Manuel
AU - Bobes, Julio
AU - Sanjuán, Julio
AU - Bernardo, Miquel
AU - Arango, Celso
AU - Kirkbride, James b
AU - Jones, Peter B
AU - Richards, Alexander
AU - Rutten, Bart p
AU - Van os, Jim
AU - Austin-Zimmerman, Isabelle
AU - Li, Zhikun
AU - Morgan, Craig
AU - Sham, Pak c
AU - Vassos, Evangelos
AU - Wong, Chloe
AU - Bentall, Richard
AU - Fisher, Helen l
AU - Murray, Robin M
AU - Alameda, Luis
AU - Di Forti, Marta
N1 - Funding Information:
EU-GEI is the acronym of the project ‘European network of National Schizophrenia Networks Studying Gene-Environment Interactions’. The research leading to these results has received funding from the European Community's Seventh Framework Programme under grant agreement No. HEALTH-F2-2010-241909 (Project EU-GEI). Brazilian data included in the EU-GEI consortium were funded by the São Paulo Research Foundation – FAPESP, Brazil (grant number 2012/05178-0). G. T. and M. D. F. were supported by the Medical Research Council (MRC) – UKRI [MR/T007818/1]. This work represents independent research part supported by The Swiss National Science Foundation (no 171804 to LA). C. M. and H. L. F. were supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King's College London [ES/S012567/1]. J. B. K. was supported by National Institute for Health Research (NIHR), University College London Hospital, Biomedical Research Centre (BRC), and E. V. was supported by the NIHR Maudsley BRC at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed in this publication are those of the authors and not necessarily those of the ESCR, the NHS, the NIHR, the Department of Health and Social Care or King's College London. C. A. was supported by the Spanish Ministry of Science and Innovation. Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024), co-financed by ERDF Funds from the European Commission, ‘A way of making Europe’, CIBERSAM. Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds. European Union Seventh Framework Program under grant agreements FP7-4-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7- HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); and European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking (grant agreement No 115916, Project PRISM, and grant agreement No 777394, Project AIMS-2-TRIALS), Fundación Familia Alonso and Fundación Alicia Koplowitz.
R. M. M. reports personal fees from Janssen, Lundbeck, Sunovion and Otsuka, outside of the submitted work. M. D. F. reports personal fees from Janssen, outside the submitted work. M. B. reports grants and personal fees from Adamed, Janssen-Cilag, Otsuka and Abbiotics; personal fees from Angelini and Casen Recordati; and grants from Lundbeck and Takeda, outside of the submitted work. C. A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Boehringer, Gedeon Richter, Janssen Cilag, Lundbeck, Minerva, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. M. Q. has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of Adamed, Angelini, Casen Recordati, Janssen-Cilag, Lundbeck, Otsuka, Menarini and Takeda.
Publisher Copyright:
Copyright © The Author(s), 2023. Published by Cambridge University Press.
PY - 2023/11
Y1 - 2023/11
N2 - BACKGROUND: Childhood adversity and cannabis use are considered independent risk factors for psychosis, but whether different patterns of cannabis use may be acting as mediator between adversity and psychotic disorders has not yet been explored. The aim of this study is to examine whether cannabis use mediates the relationship between childhood adversity and psychosis. METHODS: Data were utilised on 881 first-episode psychosis patients and 1231 controls from the European network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Detailed history of cannabis use was collected with the Cannabis Experience Questionnaire. The Childhood Experience of Care and Abuse Questionnaire was used to assess exposure to household discord, sexual, physical or emotional abuse and bullying in two periods: early (0-11 years), and late (12-17 years). A path decomposition method was used to analyse whether the association between childhood adversity and psychosis was mediated by (1) lifetime cannabis use, (2) cannabis potency and (3) frequency of use. RESULTS: The association between household discord and psychosis was partially mediated by lifetime use of cannabis (indirect effect coef. 0.078, s.e. 0.022, 17%), its potency (indirect effect coef. 0.059, s.e. 0.018, 14%) and by frequency (indirect effect coef. 0.117, s.e. 0.038, 29%). Similar findings were obtained when analyses were restricted to early exposure to household discord. CONCLUSIONS: Harmful patterns of cannabis use mediated the association between specific childhood adversities, like household discord, with later psychosis. Children exposed to particularly challenging environments in their household could benefit from psychosocial interventions aimed at preventing cannabis misuse.
AB - BACKGROUND: Childhood adversity and cannabis use are considered independent risk factors for psychosis, but whether different patterns of cannabis use may be acting as mediator between adversity and psychotic disorders has not yet been explored. The aim of this study is to examine whether cannabis use mediates the relationship between childhood adversity and psychosis. METHODS: Data were utilised on 881 first-episode psychosis patients and 1231 controls from the European network of national schizophrenia networks studying Gene-Environment Interactions (EU-GEI) study. Detailed history of cannabis use was collected with the Cannabis Experience Questionnaire. The Childhood Experience of Care and Abuse Questionnaire was used to assess exposure to household discord, sexual, physical or emotional abuse and bullying in two periods: early (0-11 years), and late (12-17 years). A path decomposition method was used to analyse whether the association between childhood adversity and psychosis was mediated by (1) lifetime cannabis use, (2) cannabis potency and (3) frequency of use. RESULTS: The association between household discord and psychosis was partially mediated by lifetime use of cannabis (indirect effect coef. 0.078, s.e. 0.022, 17%), its potency (indirect effect coef. 0.059, s.e. 0.018, 14%) and by frequency (indirect effect coef. 0.117, s.e. 0.038, 29%). Similar findings were obtained when analyses were restricted to early exposure to household discord. CONCLUSIONS: Harmful patterns of cannabis use mediated the association between specific childhood adversities, like household discord, with later psychosis. Children exposed to particularly challenging environments in their household could benefit from psychosocial interventions aimed at preventing cannabis misuse.
UR - http://www.scopus.com/inward/record.url?scp=85179647128&partnerID=8YFLogxK
U2 - 10.1017/S0033291723000995
DO - 10.1017/S0033291723000995
M3 - Article
SN - 0033-2917
VL - 53
SP - 7375
EP - 7384
JO - Psychological Medicine
JF - Psychological Medicine
IS - 15
ER -